March 12 - 15, 2020
Westin Denver Downtown
Abstract submission deadline: Tuesday, December 31
Advance registration deadline: Monday, February 3
Thursday, March 12, 2020
Friday, March 13, 2020
Saturday, March 14, 2020
Sunday, March 15, 2020
Thursday, March 12
Welcome and Opening Keynote Addresses6-7:30 p.m.
Opening Keynote Addresses
Title to be announcedRobert A. Gatenby, Moffit Cancer Center, Tampa, Florida
Title to be announcedCharlie Swanton, The Francis Crick Institute and UCL Cancer Institute, London, United Kingdom
Opening Reception7:30-10 p.m.
Top of pageFriday, March 13
Continental Breakfast7-8 a.m.
Plenary Session 1: Longitudinal Dissection of Resistance EvolutionSession Chair: Marco Gerlinger, The Institute of Cancer Research, London, United Kingdom8-10 a.m.
Jeffrey A. Engelman, Novartis Institutes for BioMedical Research, Cambridge, Massachusetts
Trever G. Bivona, University of California San Francisco, San Francisco, California
2 short talks from proffered abstracts
Panel Discussion: Genetic, Epigenetic, and Functional Heterogeneity in Cancer: Which One(s) Can We Call Evolution?Panel Moderator: Robert Gillies, Moffitt Cancer Center, Tampa, Florida10:30-11:30 a.m.
Panelists:Andrew Feinberg, Johns Hopkins School of Medicine, Baltimore, MarylandRobert Gatenby, Moffit Cancer Center, Tampa, FloridaKornelia Polyak, Dana-Farber Cancer Institute, Boston, MassachusettsCharlie Swanton, The Francis Crick Institute and UCL Cancer Institute, London, United Kingdom
Poster Session A / Lunch11:30 a.m.-2 p.m.
Plenary Session 2: Clonal Evolution Part ISession Chair: Robert J. Gillies, Moffitt Cancer Center, Tampa, Florida2-4 p.m.
Iñigo Martincorena, Wellcome Trust Sanger Institute, Hinxton, United Kingdom
Louis Vermeulen, Academic Medical Center, Amsterdam, Netherlands
Robert J. Gillies
Plenary Session 3: Generation of Genomic and Epigenomic DiversitySession Chair: Angelika Amon, Massachusetts Institute of Technology, Cambridge, Massachusetts4:15-6:15 p.m.
Andrew P. Feinberg, Johns Hopkins School of Medicine, Baltimore, Maryland
Reuben S. Harris, University of Minnesota, Minneapolis Minnesota
Susan Rosenberg, Baylor College of Medicine, Houston, Texas
Evening Off / Dinner on Own6:15 p.m.
Top of pageSaturday, March 14
Continental Breakfast7-8 a.m.
Plenary Session 4: Microenvironmental SelectionSession Chair: Kornelia Polyak, Dana-Farber Cancer Institute, Boston, Massachusetts8-10 a.m.
James V. DeGregori, University of Colorado, Aurora, Colorado
Dan A. Landau, Meyer Cancer Institute, Cornell University, New York, New York
Plenary Session 5: Mechanisms and Dynamics of Resistance Emergence Part ISession Chair: Andriy Marusyk, Moffitt Cancer Center, Tampa, Florida10:30 a.m.-12:30 p.m.
Michael T. Hemann, David H. Koch Institute for Integrative Cancer Research at MIT, Cambridge, Massachusetts
Max Diehn, Stanford University, School of Medicine, Stanford, California
Lunch on Own12:30-2 p.m.
Plenary Session 5: Mechanisms and Dynamics of Resistance Emergence Part IISession Chair: Ivana Bozic, University of Washington, Seattle, Washington2-5 p.m.
Ira Mellman, Genentech, Inc., South San Francisco, California
Jennifer Wargo, The Unviersity of Texas MD Anderson Cancer Center, Houston, Texas
1 short talk from proffered abstract
Plenary Session 5: Mechanisms and Dynamics of Resistance Emergence Part II (continued)
Paul S. Mischel, University of California San Diego, San Diego, California
Additional speaker to be announced
Poster Session B / Reception5-7 p.m.
Dinner on Own7 p.m.
Sunday, March 15
Plenary Session 6: Evolutionary Guided (Adaptive) Therapy to Prevent Emergence of ResistanceSession Chair: Carlo C. Maley, Arizona State University, Tempe, Arizona8-10 a.m.
Rong Li, Johns Hopkins University, Baltimore, Maryland
Alberto Bardelli, Candiolo Cancer Institute IRCCS, University of Turin, Italy
Carlo C. Maley
Plenary Session 7: Clonal Evolution Part IISession Chair: Christina Curtis, Stanford University School of Medicine, Stanford, California10:30 a.m.-12:30 p.m.
Andrea Sottoriva, The Institute of Cancer Research, London, United Kingdom (ICR)
Nicholas E. Navin, The University of Texas MD Anderson Cancer Center, Houston, Texas
Closing Remarks12:30 p.m.
Top of page